Areas of Interest

Oncology

Our greatest oncology interests lie in a variety of areas:

Novel assets in the following cancer areas:

  • Novel immunotherapy approaches
  • Antibody Drug Conjugates (ADCs)
  • Novel tumor metabolism pathway modulators
  • Novel epigenetic modulators
  • Novel protein homeostasis pathway modulators
  • Cancer stem cell and development pathway modulators

Emphasis on the following cancer indications

  • Lung cancer - NSCLC and SCLC
  • Gl cancers, in particular metastatic CRC, gastric, and HCC
  • Breast malignancies

Neuroscience

Our greatest interests lie in the following areas:

Neurodegenerative diseases

  • Novel therapeutic approaches for disease modification in neurodegenerative diseases, especially Alzheimer’s Disease and Parkinson’s Disease
  • Novel treatments that address the symptoms of neurodegenerative disease including psychosis, cognitive impairment, agitation, mood and sleep

Pain and Migraine

  • Novel approaches to treat chronic neuropathic, inflammatory and visceral pain
  • Migraine prophylaxis

Neuropsychiatric Symptoms of Disease

  • Late stage opportunities to mood disorders with novel mechanisms
  • Psychosis and agitation associated with indications such as Alzheimer’s disease and Parkinson’s disease

Other areas of consideration

  • Novel, transformative therapeutic approaches for additional diseases including: Epilepsy, Bipolar Disorders, Depression, Schizophrenia, ADHD, Autism, PTSD, and Anxiety

Diabetes

Our greatest interests lie in the following areas:

  • Next-generation prandial or basal insulins (especially ultra-rapid, long-acting, high-concentration, or glucose-responsive, but also novel combinations, thermostable, or oral)
  • Oral GLP-1/dual-acting GLP-1 mimetics
  • Next-generation glucagons (soluble and/or emergency)
  • Novel insulin sensitizers
  • Beta cell health (increased regeneration/proliferation/transdifferentiation; reduced apoptosis)
  • Modulation of white adipose to brown adipose tissue conversion
  • Pathways relating to lipotoxicity
  • Diabetic kidney disease/nephropathy
  • NASH
  • Novel approaches relevant to the development of an artificial pancreas
  • Novel insulin secretagogues
  • Breakthrough diabetes device technology
  • Reduction of hepatic glucose output
  • Other endocrine disorders (e.g., growth disorders and major unmet medical needs)

Note: Highest priority for molecules is given to those validated as ‘Glucose-Plus’ agents (e.g., drugs that reduce HbA1c and elicit weight loss and/or improvements in other CV risk factors, etc.); interest includes both small and large molecules, and Type 2 and Type 1 diabetes

Autoimmune

Our greatest interests lie in the following areas:

The autoimmune platform’s mission is to address unmet medical needs with best-in-disease or best-in-class medicines and to deliver unparalleled customer experiences. With a strong focus on small molecule and biologics in the following indications:

  • Rheumatoid arthritis
  • Psoriasis
  • System lupus erythematosus
  • Crohn’s disease
  • Ulcerative colitis
  • Multiple sclerosis

Lilly Autoimmune is also interested in the following indications:

  • Ankylosing spondylitis
  • Psoriatic arthritis
  • Lupus nephritis

Biotherapeutic Technologies

Our greatest interests lie in the following areas:

  • Protein expression / production technologies
    • Non-mammalian / microbial expression and production systems
    • Cell culture
    • Antibody / Fab production systems
    • Early identification of high expressing cell lines
    • Purification processes
    • Glycosylation
    • Formulation design
  • Protein Optimization Engineering
    • Bi-specific / multi-functional platforms
    • mA b / alternative scaffolds
    • Half-life extension of antibodies, peptides and proteins
      • alternatives to PEG-ylation
    • Site-specific chemical modification
  • Antibody Drug Conjugates: novel linker, conjugation chemistries and warheads
  • Peptide chemistry: semi-synthetic, recombinant and conjugation chemistries
  • Protein: protein interactions
  • Assessment of biodistribution
  • Drug delivery
    • Oral
    • Blood Brain Barrier
    • Invivo delivery of nucleic acids(shRNA, miRNA, antisense, mRNA

Emerging Markets

Our greatest interests lie in the following areas:

In-Licensing and Co-Development

Oncology

  • Thoracic Cancer
  • Breast Cancer
  • Gastrointestinal: Gastric, Colorectal, Hepatocellular Carcinoma, Pancreatic Cancer
  • Immuno-oncology
  • Hematological Malignancies

Neuroscience

  • Neurodegenerative Disorders: Approaches that affect disease progression or modification and/or address major symptoms of the disease
  • Psychiatric Disorders: With potential differentiation from standards of care
  • Pain and Migraine

Diabetes

  • Novel oral anti-diabetic agents
  • Ultra rapid-acting insulins

Out-Licensing

  • Regional/local development of select Lilly pipeline molecules

Strategic Partnerships

  • Geographic Commercial Partnerships, Local Manufacturing Partnerships, Public-Private Partnerships

Drug Delivery and Devices

Our greatest interests lie in the following areas:

Advances in auto-injector pens and wearable injector platforms, including:

  • Wireless remote medication monitoring
  • High-volume applications
  • High-viscosity applications

Advances in “patch pump” delivery technology, including:

  • Subcutaneous delivery
  • Wireless remote control and monitoring
  • Patient-intuitive applications

Oral peptide delivery technology

Advances in Artificial Pancreas Device Systems (APDS)

New technology to deliver therapeutic agents:

  • To the central nervous system across the blood-brain barrier
  • Via needle free technologies
  • Transdermal patches
  • Time-action modulation (small and large molecules)
  • Preservation technology to enable multi-use biological preps

High-dose biological delivery

  • Formulation technology to reduce viscosity of biologics in solution
  • Device technology to deliver high-volume (>2ml) and/or high viscosity (>10 cpd) biologic solutions

Delivery of multi-pharmacology (enabling technologies including devices)

  • Fixed-dose combinations (small and large molecule)
  • Bi-specific or combined dose antibodies

Regional Innovation

Our greatest interests lie in the following areas:

As part of Lilly's overall Research and Development strategy, we focus on "hot spots" of innovation. Regional collaborations link outstanding science with the expertise of Lilly scientists across a broad range of therapeutic areas to form the next generation of breakthrough biopharmaceutical companies. We offer access to our industry experts, including Lilly's Chorus* team, whom provide insights on a number of additional areas: regulatory, commercial, reimbursement, CM&C, etc.

  • New York City — The City of New York is home to a number of premier life science Universities and has the highest number of publications of any metropolitan area in the U.S. Lilly’s New York City Research and Development site works to discover and advance a diverse Oncology pipeline. Lilly is a limited partner in both the City of New York Early-Stage Life Sciences Fund and the Accelerator IV Fund.
  • United Kingdom — The U.K. has a high concentration of world-class research institutions and the highest rate of new biotech start-ups outside the U.S. Lilly’s Erl Wood Research & Development site near London focuses on neuroscience research and development of Lilly’s pipeline across several therapeutic areas. We have built on these links with a network of virtual innovation offices in biotech centers across the U.K. Lilly is a limited partner in the Epidarex Capital II Fund.
  • Seattle — The growing scientific community of Seattle has a number of proven leaders in discovery and development of new and innovative medicines. Washington consistently ranks near the top five states by deal number and top ten states for investment dollars. Although Lilly does not have a physical presence in Seattle, Lilly actively participates in shaping medicines across a variety of therapeutic areas. Lilly is a limited partner in the Accelerator IV fund.

*Chrorus is the early phase virtual drug development team within Lilly. It is a full-service R&D unit within Lilly that specializes in drug development from candidate selection to clinical proof-of-concept. Chorus quickly achieves proof-of-concept at a low cost while positioning successful projects for “pharma quality” late-stage development.

Cardiovascular

Our greatest interests lie in the following areas:

Cardio In Scope:

  • LDL-C Reduction for Patients with Severe Hypercholesterolemia
  • CV Event Reduction in Patients/Mixed Dyslipidemia (HDL-C)
  • Peripheral Arterial Disease (PAD) (small vessel disease)
  • Chronic Heart Failure (CHF)
  • Resistant Hypertension
  • Acute Heart Failure
  • Event Reduction through Plaque Stabilization
  • Stroke Prophylaxis in Atrial Fibrillation

Cardio Out of Scope (unless Phase 3):

  • Stable Angina (no option patient)
  • Acute Stroke
  • Ventricular Arrhythmias (adjunct to device)
  • Acute MI/Myocardial Protection
  • Abdominal Aortic Aneurysm (AAA)